Ensol Biosciences Inc.

CEO : Hae-Jin Kim

As a bio big data-based biopharmaceutical company that develops global innovative new drugs for diseases without therapeutic alternatives worldwide, such as degenerative disc, degenerative arthritis, TNBC, Alzheimer’s disease and type 1 diabetes, Ensol Biosciences applies bio big data-based BT/IT convergence technology from the aspects of drug efficacy, mechanism and toxicity, and side effects to develop outstanding drugs with high potential, and works on various discoveries and clinical trial phases systematically.Ensol Biosciences power behind the development of innovative drugs that global pharmaceutical companies haven’t even solved yet and developing them into first-in-class drugs is in the ‘bio big data-based’ new drug candidate search platform, called KISDD, which the company has been developing and operating endlessly since the establishment of company in 2001. Ensol Biosciences creates high added value through the development of innovative new drug, licensing out and commercialization, and provides CDO service and new drug CMC consigned development service based on our new drug development technology. Also, based on the synthesis, analysis and separation technique of new drug material candidates, we offer the production/sales and analysis/separation service of phytochemical, a high-value biomaterial, and synthesis of peptides and chemicals. Main Export Product The company expanded its business to include viral transport medium and diagnostic reagents following the COVID-19 pandemic last year. The company has developed EnTM, a viral transport medium(VTM), as a know-how in the CMC field accumulated in the process of developing new drugs. EnTM is a tool that collects and safely preserves virus and bacterial samples from human nasal and mouth for use in diagnostic testing of the viral epidemic, COVID-19.